Systemic inflammation and obstructive sleep apnea syndrome (OSA): the role of C–reactive protein (CRP)

The presence of sleep-related disorders, particularly obstructive sleep apnea syndrome (OSA), instigates pathological changes during sleep, giving rise to frequent hypoxic episodes that generate elevated levels of a broad spectrum of inflammatory cytokines. C-reactive protein (CRP), a biomarker signifying the presence and intensity of inflammation, is frequently detected in elevated serum or plasma concentrations, correlating with the number of respiratory events, especially in moderate and severe forms, across both adults and children. Various available therapeutic approaches demonstrate the capacity to diminish serum levels, although the minimum duration of usage typically extends between 2-6 months. In the case of older individuals, OSA commonly coexists with additional conditions, further augmenting the baseline inflammatory level. This accelerated disease progression amplifies mortality rates, incurs heightened costs, and significantly diminishes the overall quality of life.